Tildrakizumab (IL23A) Antibody, Monoclonal
| Code | Size | Price |
|---|
| PSI-10-581-0.1mg | 0.1mg | £657.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Isotype: IgG1-kappa
Antibody Clonality: Recombinant Antibody
Regulatory Status: RUO
Shipping:
blue ice
Storage:
Store at -80˚C
Documents
Further Information
Additional Names:
MK-3222, SCH900222
Background:
Tildrakizumab is a high-affinity, humanized, IgG1 ? antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis 3.The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy in March 2018. The approved recommended dosage of ILUMYA is a subcutaneous injection of 100 mg at Weeks 0, 4, and every 12 weeks thereafter 7.
A study was performed on the pharmacokinetics of this drug on various ethnicities. The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects 5.
Buffer:
PBS buffer pH7.5
Concentration:
batch dependent
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
Humanized / IL23A [Homo sapiens]
NCBI Organism:
homo sapiens
Purification:
>95%
Research Area:
Drug Analogues
Source:
CHO cells
User NOte:
Optimal dilutions for each application to be determined by the researcher.